Form 4: Cidara Therapeutics Director Acquires 19,000 Stock Options

Director Chrysa Mineo acquired 19,000 stock options in Cidara Therapeutics, Inc. on December 17, 2024.

Summary

• Chrysa Mineo, a director at Cidara Therapeutics, Inc., acquired 19,000 stock options on December 17, 2024.
• The options have an exercise price of $22.81.
• The options vest in 36 equal monthly installments starting from December 17, 2024.
• The options expire on December 16, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows alignment of interests between the director and the company's performance. It is not a major event, but it is a positive sign.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

This is a standard transaction for a director of a public company, often part of their compensation package.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry, similar to companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedule of 36 months is also typical for such grants, aligning with industry norms for long-term incentives.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging actions that increase shareholder value.

Key Dates

Keywords

stock options, director, insider trading, Cidara Therapeutics, CDTX, equity, vesting